Clinical Trials · NCT01584232
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 361
- Start date
- Apr 2012
- Locations
- 15 sites, Japan
- Primary endpoint
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks